We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+7.24%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$2.14B
AUM Growth
+$218M
Cap. Flow
+$172M
Cap. Flow %
8.07%
Top 10 Hldgs %
26.01%
Holding
154
New
13
Increased
61
Reduced
17
Closed
10

Top Buys

Rank Stock Value
1
GTT
GTT Communications, Inc.
GTT
+$19.7M
2
ANET icon
Arista Networks
ANET
+$17.8M
3
VRNS icon
Varonis Systems
VRNS
+$17.3M
4
ROP icon
Roper Technologies
ROP
+$16.3M
5
MIC
Macquarie Infrastructure Holdings, LLC
MIC
+$15.9M

Top Sells

Rank Stock Value
1
TTD icon
Trade Desk
TTD
+$16.9M
2
TWLO icon
Twilio
TWLO
+$7.85M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$6.12M
4
LOXO
Loxo Oncology, Inc
LOXO
+$5.96M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$5.72M

Sector Composition

Rank Sector Weight
1 Healthcare 38.18%
2 Technology 17.61%
3 Consumer Discretionary 12.18%
4 Industrials 9.62%
5 Utilities 3.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MYOK
76
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$7.42M 0.35%
152,000
+42,000
+38% +$2.18M
RCKT icon
77
Rocket Pharmaceuticals
RCKT
$346M
$7.4M 0.35%
+394,585
New +$6.43M
ALNY icon
78
Alnylam Pharmaceuticals
ALNY
$38.3B
$7.38M 0.35%
62,000
-28,000
-31% -$3.61M
MNTA
79
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$7.26M 0.34%
+400,000
New +$6.67M
EXR icon
80
Extra Space Storage
EXR
$32.2B
$7.25M 0.34%
83,000
+1,000
+1% +$84.1K
GWPH
81
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$7.16M 0.34%
63,500
– –
XNCR icon
82
Xencor
XNCR
$1.48B
$6.83M 0.32%
228,000
-85,000
-27% -$2.22M
VBIV
83
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$6.47M 0.3%
61,667
– –
CERN
84
DELISTED
Cerner Corp
CERN
$6.28M 0.29%
108,200
– –
VIRX
85
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$6.16M 0.29%
64,727
– –
BMRN icon
86
BioMarin Pharmaceuticals
BMRN
$11.9B
$6.08M 0.28%
75,000
– –
SUPN icon
87
Supernus Pharmaceuticals
SUPN
$2.74B
$5.95M 0.28%
130,000
– –
ATHN
88
DELISTED
Athenahealth, Inc.
ATHN
$5.29M 0.25%
37,000
– –
EXAS
89
DELISTED
Exact Sciences
EXAS
$5.28M 0.25%
131,000
+31,000
+31% +$1.51M
AKCA
90
DELISTED
Akcea Therapeutics Inc
AKCA
$4.48M 0.21%
175,000
-245,000
-58% -$5.27M
RARE icon
91
Ultragenyx Pharmaceutical
RARE
$2.55B
$4.46M 0.21%
87,400
– –
LKFT
92
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.84B
$3.99M 0.19%
40,000
-12,000
-23% -$1.29M
RGEN icon
93
Repligen
RGEN
$8.37B
$3.98M 0.19%
110,000
– –
DBVT
94
DBV Technologies
DBVT
$807M
$3.92M 0.18%
17,000
– –
MGNX icon
95
MacroGenics
MGNX
$241M
$3.7M 0.17%
147,000
– –
ECYT
96
DELISTED
Endocyte, Inc. Common Stock
ECYT
$3.18M 0.15%
+350,000
New +$1.93M
BEP icon
97
Brookfield Renewable
BEP
$9.72B
$3.08M 0.14%
185,774
+39,782
+27% +$680K
SLDB icon
98
Solid Biosciences
SLDB
$773M
$3M 0.14%
+26,667
New +$9.01M
IRWD icon
99
Ironwood Pharmaceuticals
IRWD
$637M
$2.96M 0.14%
229,248
– –
MDGL icon
100
Madrigal Pharmaceuticals
MDGL
$12.4B
$2.92M 0.14%
+25,000
New +$3.09M
2 3
4
5 6

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.03B AUM 40.55% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return

Eventide Asset Management's Q1 2018 Portfolio in Review

As of Q1 2018, Eventide Asset Management held 154 positions worth $2.14B, up 11% from $1.92B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Eventide Asset Management deployed $172M of net new capital in Q1 2018, opening 13 new positions and adding to 61 existing holdings. Its largest new stake was Arista Networks: 1,056,000 shares worth $16.9M.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 37% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Trade Desk, an estimated $16.9M trimmed.

  • Eventide Asset Management's largest Q1 2018 buy was Arista Networks: 1,056,000 shares worth $16.9M.
  • Eventide Asset Management added most to GTT Communications, Inc. in Q1 2018, an estimated $19.7M increase.
  • Eventide Asset Management's biggest Q1 2018 reduction was Trade Desk, cutting an estimated $16.9M.
  • Eventide Asset Management fully exited Protagonist Therapeutics in Q1 2018, selling an estimated $5.72M.
  • Eventide Asset Management's ten largest holdings make up 26% of its $2.14B portfolio in Q1 2018.
  • Eventide Asset Management opened 13 new positions and closed 10 in Q1 2018.
  • Eventide Asset Management's portfolio value rose 11% quarter-over-quarter to $2.14B.

Based on Eventide Asset Management's 13F filing for Q1 2018, filed 15 May 2018.